BioShares Biotechnology shows prevailing Real Value of $33.26 per share. The current price of the entity is $30.75. At this time the entity appears to be under valued. Macroaxis approximates value of BioShares Biotechnology from analyzing the entity fundamentals such as Three Year Return of
1.36%, Price to Earning of 39.87times and Price to Sales of 1.99times as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.
|Time Horizon||30 Days Login to change|
BioShares Biotechnology Clinical Trials is second largest ETF in price to earning as compared to similar ETFs. It is the top ETF in one year return as compared to similar ETFs reporting about 1.41 of One Year Return per Price to Earning.
BioShares Biotechnology is not too volatile asset. Calculation of real value of BioShares Biotechnology is based on 1 month time horizon. Increasing BioShares Biotechnology time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.